A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab.

Autor: Saito N; Department of Gastroenterology Gunma Saiseikai Maebashi Hospital Maebashi Japan., Hatanaka T; Department of Gastroenterology Gunma Saiseikai Maebashi Hospital Maebashi Japan., Nakano S; Department of Gastroenterology Gunma Saiseikai Maebashi Hospital Maebashi Japan., Hazama Y; Department of Gastroenterology Gunma Saiseikai Maebashi Hospital Maebashi Japan., Yoshida S; Department of Gastroenterology Gunma Saiseikai Maebashi Hospital Maebashi Japan., Hachisu Y; Department of Gastroenterology Gunma Saiseikai Maebashi Hospital Maebashi Japan., Tanaka Y; Department of Gastroenterology Gunma Saiseikai Maebashi Hospital Maebashi Japan., Yoshinaga T; Department of Gastroenterology Gunma Saiseikai Maebashi Hospital Maebashi Japan., Kashiwabara K; Department of Pathology Gunma Saiseikai Maebashi Hospital Maebashi Japan., Kubo N; Department of Surgery Gunma Saiseikai Maebashi Hospital Maebashi Japan., Hosouchi Y; Department of Surgery Gunma Saiseikai Maebashi Hospital Maebashi Japan., Tojima H; Department of Gastroenterology and Hepatology Gunma University Graduate School of Medicine Maebashi Japan., Kakizaki S; Department of Gastroenterology and Hepatology Gunma University Graduate School of Medicine Maebashi Japan.; Department of Clinical Research National Hospital Organization Takasaki General Medical Center Takasaki Japan., Uraoka T; Department of Gastroenterology and Hepatology Gunma University Graduate School of Medicine Maebashi Japan.
Jazyk: angličtina
Zdroj: Clinical case reports [Clin Case Rep] 2022 Jul 25; Vol. 10 (7), pp. e6129. Date of Electronic Publication: 2022 Jul 25 (Print Publication: 2022).
DOI: 10.1002/ccr3.6129
Abstrakt: An 81-year-old man initially underwent right hepatic lobectomy for liver cancer and was pathologically diagnosed with combined hepatocellular and cholangiocarcinoma (CHC). At 13 months after resection, multiple lymph node metastases were observed. We started atezolizumab plus bevacizumab (Atez/Bev), achieving a 7.5-month progression-free survival. Atez/Bev might exhibit efficacy for CHC patients.
Competing Interests: Takeshi Hatanaka received lecture fee from Eisai. None of the other authors have potential conflicts of interest to declare.
(© 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje